切换至 "中华医学电子期刊资源库"

中华细胞与干细胞杂志(电子版) ›› 2023, Vol. 13 ›› Issue (06) : 346 -354. doi: 10.3877/cma.j.issn.2095-1221.2023.06.004

论著

miR-340-5p调控PDE4D表达对胃癌细胞顺铂耐药性的影响
吴亚萍1, 吴颖1,()   
  1. 1. 226500 南通,江苏南通大学附属如皋医院普外科
  • 收稿日期:2024-01-18 出版日期:2023-12-01
  • 通信作者: 吴颖

Effect of miR-340-5p regulating PDE4D expression on cisplatin resistance of gastric cancer cells

Yaping Wu1, Ying Wu1,()   

  1. 1. Department of General Surgery, Nantong University Affiliated Rugao Hospital, Nantong, Jiangsu 226500, China
  • Received:2024-01-18 Published:2023-12-01
  • Corresponding author: Ying Wu
引用本文:

吴亚萍, 吴颖. miR-340-5p调控PDE4D表达对胃癌细胞顺铂耐药性的影响[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(06): 346-354.

Yaping Wu, Ying Wu. Effect of miR-340-5p regulating PDE4D expression on cisplatin resistance of gastric cancer cells[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(06): 346-354.

目的

探讨miR-340-5p调控磷酸二酯酶4D(PDE4D)表达对胃癌细胞顺铂(DDP)耐药性的影响。

方法

将胃癌细胞AGS连续暴露于0.1 ~ 1 μg/mL DDP中来构建耐DDP的胃癌细胞系AGS/DDP,1、3、5、7 μg/mL DDP处理AGS、AGS/DDP细胞,CCK-8检测细胞活力及IC50;qRT-PCR检测miR-340-5p表达量;Western blot检测PDE4D蛋白表达水平;验证miR-340-5p与PDE4D靶向关系;分别将miR-340-5p mimics、siRNA PDE4D转染于AGS/DDP细胞,miR-340-5p mimics和pcDNA-PDE4D共转染于AGS/DDP细胞,将转染成功的AGS/DDP细胞以及未转染AGS/DDP细胞分别用5 μg/mL DDP处理,观察AGS/DDP细胞增殖、迁移和侵袭变化。两组间比较采用独立样本t检验,多组间比较采用单因素方差分析和SNK-q检验。

结果

与AGS细胞相比,AGS/DDP细胞在1、3、5、7 μg/mL DDP处理时的细胞活力升高,IC50值[(5.89 ± 0.27)比(1.46 ± 0.11)μg/mL]升高;与AGS细胞相比,AGS/ DDP细胞中miR- 340- 5p的表达(0.34 ± 0.17比1.00 ± 0.00)降低,而PDE4D蛋白水平(1.83 ± 0.11比0.25 ± 0.01)升高;PDE4D为miR-340-5p靶基因;过表达miR-340-5p或敲低PDE4D可抑制AGS/ DDP细胞增殖、迁移[(54.17 ± 4.12)比(26.00 ± 2.28)个、(55.00 ± 4.43)比(24.50 ± 2.07)个]与侵袭[(37.17 ± 3.19)比(19.33 ± 1.63)个、(38.33 ± 3.14)比(16.33 ± 1.63)个];上调PDE4D表达可逆转过表达miR-340-5p对AGS/DDP细胞增殖、迁移和侵袭的抑制作用(P均< 0.05)。

结论

miR-340- 5p通过靶向下调PDE4D表达抑制AGS/DDP细胞增殖、迁移和侵袭,降低其对DDP的耐药性。

Objective

To investigate the effect of miR-340-5p regulating the expression of cAMPspecific 3', 5'-cyclic phosphodiesterase 4D (PDE4D) on the drug resistance of gastric cancer cells to cisplatin (DDP) .

Methods

The gastric cancer cell line AGS was continuously exposed to 0.1-1 μg/mL DDP to construct a DDP-resistant gastric cancer cell line named AGS/DDP. AGS and AGS/DDP cells were treated with 1, 3, 5, 7 μg/mL DDP, and cell viability and IC50 were detected by CCK-8; qRT-PCR was used to detect the expression of miR-340-5p; and Western blot was used to detect the PDE4D protein expression level; the targeting relationship between miR- 340- 5p and PDE4D was verified. At the same time, the miR-340-5p mimics and siRNA PDE4D were transfected into AGS/DDP cells respectively. The miR-340-5p mimics and pcDNA-PDE4D were co-transfected into AGS/DDP cells, the successfully transfected AGS/DDP cells and untransfected AGS/DDP cells were treated with 5 μg/mL DDP, and the changes of AGS/DDP cell proliferation, migration and invasion were observed. Independent sample t-test was used for comparison between two groups, and univariate analysis of variance and SNK-q test were used for comparison between multiple groups.

Results

Compared with AGS cells, the cell viability of AGS/DDP cells was increased when treated with 1, 3, 5, and 7 μg/mL DDP, and the IC50 value was significantly increased [ (5.89 ± 0.27) μg/ mL vs (1.46 ± 0.11) μg/mL, P < 0.05]; compared with AGS cells, the expression of miR-340-5p in AGS/ DDP cells was decreased (0.34 ± 0.17 vs 1.00 ± 0.00, P < 0.05), while the level of PDE4D protein was significantly increased (1.83 ± 0.11 vs 0.25 ± 0.01, P < 0.05) ; PDE4D was the miR- 340- 5p target gene; overexpression of miR-340-5p or knockdown of PDE4D inhibited proliferation, migration [ (54.17 ± 4.12) vs (26.00 ± 2.28), (55.00 ± 4.43) vs (24.50 ± 2.07) ] and invasion [ (37.17 ± 3.19) vs (19.33 ± 1.63), (38.33 ± 3.14) vs (16.33 ± 1.63) ] of AGS/DDP cells (P < 0.05) ; upregulation of PDE4D expression reversed the inhibitory effect of overexpression of miR-340-5p on proliferation, migration, and invasion of AGS/DDP cells (P < 0.05) .

Conclusion

MiR-340-5p inhibits the proliferation, migration and invasion of AGS/DDP cells by targeting down-regulation of PDE4D expression to reduce their resistance to DDP.

表1 qRT-PCR引物序列
表2 DDP对AGS、AGS/DDP细胞活力的影响(±s
表3 miR-340-5p和PDE4D在胃癌细胞AGS和DDP耐药细胞AGS/DDP中表达(±s
图1 PDE4D在AGS和AGS/DDP细胞中表达水平
图2 预测的miR-340-5p与PDE4D的结合位点
表4 Western blot检测上调miR-340-5p后PDE4D蛋白表达水平变化(±s
图3 上调miR-340-5p表达后AGS和AGS/DDP细胞中PDE4D蛋白表达情况
表6 qRT-PCR检测转染miR-340-5p mimic后AGS/DDP细胞中miR-340-5p和PDE4D mRNA表达变化(±s
表7 上调miR-340-5p表达联合DDP对AGS/DDP细胞增殖的影响(±s
表8 上调miR-340-5p表达联合DDP对AGS/DDP细胞迁移与侵袭的影响(个,±s
图4 光学显微镜下观察上调miR-340-5p表达联合DDP对AGS/DDP细胞迁移和侵袭的影响(结晶紫染色,×200)注:与DDP和转染miR-NC联合DDP干预的细胞比较,上调miR-340-5p表达联合DDP干预的AGS/DDP细胞迁移与侵袭的细胞数降低
表9 下调PDE4D表达联合DDP对AGS/DDP细胞增殖的影响(±s
表10 下调PDE4D表达联合DDP对AGS/DDP细胞迁移与侵袭的影响(个,±s
图5 Western blot检测转染siRNA PDE4D后AGS/DDP细胞中PDE4D表达情况
图6 光学显微镜下观察下调PDE4D表达联合DDP对AGS/DDP细胞迁移与侵袭的影响(结晶紫染色,×200)注:与DDP和转染siRNA-NC联合DDP干预的细胞比较,下调PDE4D表达联合DDP干预的AGS/DDP细胞迁移和侵袭能力降低
表11 上调PDE4D表达逆转过表达miR-340-5p对AGS/DDP细胞增殖的影响
表12 上调PDE4D表达逆转过表达miR-340-5p对AGS/DDP细胞迁移与侵袭的影响(个,±s
图7 光学显微镜下观察上调PDE4D表达逆转过表达miR-340-5p对AGS/DDP细胞迁移与侵袭的影响(结晶紫染色,×200)注:与DDP和miR-NC+DDP干预比较,过表达miR-340-5p联合DDP干预的AGS/DDP细胞迁移与侵袭的细胞数降低;上调miR-340-5p和PDE4D表达联合DDP干预的AGS/DDP细胞迁移和侵袭能力高于过表达miR-340-5p联合DDP干预和转染miR-340-5p mimics+pcDNA-NC联合DDP干预的细胞
1
Norwood DA, Montalvan-Sanchez E, Dominguez RL, et al. Gastric Cancer: Emerging Trends in Prevention, Diagnosis, and Treatment[J]. Gastroenterol Clin North Am, 2022, 51(3):501-518.
2
Kodera Y, Yoshida K, Kochi M, et al. Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study[J]. Gastric Cancer, 2023, 26(6):1063-1068.
3
Wang H, Yang L, Liu R, et al. ADAR1 affects gastric cancer cell metastasis and reverses cisplatin resistance through AZIN1[J]. Anticancer Drugs, 2023, 34(10):1132-1145.
4
Aalami AH, Aalami F, Sahebkar A. Gastric Cancer and Circulating microRNAs: An Updated Systematic Review and Diagnostic Meta-Analysis[J]. Curr Med Chem, 2023, 30(33):3798-3814.
5
Liu C, Li S, Tang Y. Mechanism of cisplatin resistance in gastric cancer and associated microRNAs[J]. Cancer Chemother Pharmacol, 2023, 92(5):329-340.
6
Zhang, Kang, Lu, et al. LncRNA CASC11 promoted gastric cancer cell proliferation, migration and invasion in vitro by regulating cell cycle pathway[J]. Cell Cycle, 2018, 17(15): 1886–1900.
7
Zhang Z, Zhou Q, Luo F, et al. Circular RNA circ-CHI3L1.2 modulates cisplatin resistance of osteosarcoma cells via the miR-340-5p/LPAATβ axis[J]. Hum Cell, 2021, 34(5):1558-1568.
8
Liu F, Ma J, Wang K, et al. High expression of PDE4D correlates with poor prognosis and clinical progression in pancreaticductal adenocarcinoma[J]. J Cancer, 2019, 10(25):6252-6260.
9
Peng QP, Du DB, Ming Q, et al. MicroRNA 494 increases chemosensitivity to doxorubicin in gastric cancer cells by targeting phosphodiesterases 4D[J]. Cell Mol Biol (Noisy-le-grand), 2018, 64(15):62-66.
10
徐龙健,高建超,钟轩,等. 微小RNA-876-3p靶向肽基脯氨酰顺反异构酶A调控胃癌细胞增殖和顺铂耐药性的作用机制研究[J]. 中国临床药理学杂志, 2020, 36(17):2686-2690.
11
Dai X, Chen Y, Chen N, et al. KLF5-mediated aquaporin 3 activated autophagy to facilitate cisplatin resistance of gastric cancer[J]. Immunopharmacol Immunotoxicol, 2023, 45(2):140-152.
12
Chen W, Hu J, He Y, et al. The Interaction Between SMAD1 and YAP1 Is Correlated with Increased Resistance of Gastric Cancer Cells to Cisplatin[J]. Appl Biochem Biotechnol, 2023, 195(10):6050-6067.
13
Zhou C, Chen L, Chen R, et al. miR-4486 enhances cisplatin sensitivity of gastric cancer cells by restraining the JAK3/STAT3 signalling pathway[J]. J Chemother, 2022, 34(1):35-44.
14
Zhu T, Hu Z, Wang Z, et al. microRNA-301b-3p from mesenchymal stem cells-derived extracellular vesicles inhibits TXNIP to promote multidrug resistance of gastric cancer cells[J]. Cell Biol Toxicol, 2023, 39(5):1923-1937.
15
Cui F, Hao ZX, Li J, et al. SOX2 mediates cisplatin resistance in small-cell lung cancer with downregulated expression of hsa-miR-340-5p[J]. Mol Genet Genomic Med, 2020, 8(5):e1195. doi: 10.1002/mgg3.1195.
16
Song L, Duan P, Gan Y, et al. MicroRNA-340-5p modulates cisplatin resistance by targeting LPAATβ in osteosarcoma[J]. Braz J Med Biol Res, 2017, 50(5):e6359. doi: 10.1590/1414-431X20176359.
17
Hsien Lai S, Zervoudakis G, Chou J, et al. PDE4 subtypes in cancer[J]. Oncogene, 2020, 39(19):3791-3802.
18
Delyon J, Servy A, Laugier F, et al. PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma[J]. Oncogene, 2017, 36(23):3252-3262.
19
Cao B, Wang K, Liao JM, et al. Inactivation of oncogenic cAMP-specific phosphodiesterase 4D by miR-139-5p in response to p53 activation[J]. Elife, 2016, 5:e15978. doi: 10.7554/eLife.15978.
20
Zuo Y, Zheng W, Liu J, et al. MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells[J]. Neoplasma, 2020, 67(1):93-101.
21
Wang C, Wang S, Ma F, et al. miRNA-328 overexpression confers cisplatin resistance in non-small cell lung cancer via targeting of PTEN[J]. Mol Med Rep, 2018, 18(5):4563-4570.
22
Cao M, Nawalaniec K, Ajay AK,et al. PDE4D targeting enhances anti-tumor effects of sorafenib in clear cell renal cell carcinoma and attenuates MAPK/ERK signaling in a CRAF-dependent manner[J]. Transl Oncol, 2022, 19(1):101377. doi: 10.1016/j.tranon.2022.101377.
23
Mishra RR, Belder N, Ansari SA, et al. Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer[J]. Clin Cancer Res, 2018, 24(8):1987-2001.
[1] 赵向阳, 刘双池, 张懿刚, 陶滔, 谈燚. 顺铂对肝细胞癌Hep3B细胞程序性死亡配体1表达及药物敏感性的研究[J]. 中华普通外科学文献(电子版), 2024, 18(01): 51-55.
[2] 张再博, 王冰雨, 焦志凯, 檀碧波. 胃癌术后下肢深静脉血栓危险因素的Meta分析[J]. 中华普通外科学文献(电子版), 2023, 17(06): 475-480.
[3] 张生军, 赵阿静, 李守博, 郝祥宏, 刘敏丽. 高糖通过HGF/c-met通路促进结直肠癌侵袭和迁移的实验研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 21-24.
[4] 江振剑, 蒋明, 黄大莉. TK1、Ki67蛋白在分化型甲状腺癌组织中的表达及预后价值研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 623-626.
[5] 陈勇, 任建伟, 朱光发, 刘玉磊, 吴绍芹. 非移植患者侵袭性肺曲霉病32例临床特征分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(06): 809-813.
[6] 王小燕, 韩崇兰. 扁塑藤素对非小细胞肺癌细胞株A549恶性生物学行为的影响[J]. 中华肺部疾病杂志(电子版), 2023, 16(06): 822-825.
[7] 刘磊, 张琪, 范兴彪. 基于放射性特征预测肺结节侵袭性的临床应用[J]. 中华肺部疾病杂志(电子版), 2023, 16(06): 880-882.
[8] 王守森, 方翌, 冯添顺, 魏梁锋. 深度学习模型在侵袭性垂体腺瘤诊疗中的应用[J]. 中华脑科疾病与康复杂志(电子版), 2023, 13(06): 382-384.
[9] 苑乐添, 王艺霖, 沈子剑, 闫呈新. 血清GDF15、sB7-H1联合多层螺旋CT灌注成像技术对胃癌患者淋巴结转移的诊断价值[J]. 中华消化病与影像杂志(电子版), 2024, 14(01): 62-66.
[10] 葛雪梅. SOX与mFOLFOX6化疗方案对晚期胃癌的疗效与安全性[J]. 中华消化病与影像杂志(电子版), 2024, 14(01): 67-71.
[11] 韩晓娟, 徐佳倩, 朱玉兰, 王莹, 李源, 冯珺, 邵东. HHLA2过表达胃癌细胞株构建及细胞功能的初步研究[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 373-377.
[12] 钟广俊, 刘春华, 朱万森, 徐晓雷, 王兆军. MRI联合不同扫描序列在胃癌术前分期诊断及化疗效果和预后的评估[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 378-382.
[13] 孙秀艳, 徐庆蕾, 马鹏涛, 胡志元, 郭传真, 祝成红. 腹腔镜胃癌根治术中患者体温变化与压力性损伤及受压部位微环境的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 480-484.
[14] 董青, 丁飞, 郭浩, 李峰. Nesfatin-1/NUCB2在幽门螺杆菌感染相关早期胃癌患者中的表达及临床意义[J]. 中华临床医师杂志(电子版), 2023, 17(07): 783-789.
[15] 邓世栋, 刘凌志, 郭大勇, 王超, 黄忠欣, 张晖辉. 沉默SNHG1基因对膀胱癌细胞增殖、凋亡、迁移和铁死亡的影响[J]. 中华临床医师杂志(电子版), 2023, 17(07): 804-811.
阅读次数
全文


摘要